References
- D'Alò F, Voso M T, Guidi F, Massini G, Scardocci A, Sica S, Pagano L, et al. Polymorphisms of CYP1A1 and glutathione S-transferase and susceptbility to adult acute myeloid leukemia. Haematologica 2004; 89: 664–670
- Cascorbi I, Brockmöller J, Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer suscepbtility. Cancer Res 1996; 56: 4965–4969
- Voso M T, D'Aló F, Putzulu R, Mele L, Scardocci A, Chiusolo P, et al. Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. Blood 2002; 100: 2703–2707
- Voso M T, D'Alò F, Gumiero D, Guidi F, Hohau S, Leone G. The CYP1A1*2A allele is an independent prognostic factor for acute myeloid leukemia. Haematologica 2005; 90: 982–984
- Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 Trial. Blood 1998; 92: 2322–2333
- Jaffe, E S, Harris, N L, Stein, H, Vardiman, J W. In World Health Organization Classifications of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon 2001
- Pelloso L A, Chauffaille M LL, Ghaname F S, Yamamoto M, Bahia D M, Kerbauy J. Karyotype in acute myeloid leukemia: importance and type of aberrations in 30 patients at diagnosis. Rev Assoc Med Bras 2003; 49: 150–155
- Bahia D MM, Yamamoto M, Chauffaille Kimura E Y, Bordin J O, Filgueiras M A, Kerbauy J. Aberrant phenotypes in acute myeloid leukemia: a high frequency and clinical significance. Haematologica 2001; 86: 801–806
- Chauffaille M LLF, Figueiredo M S, Beltrani R, Antunes S V, Yamamoto M, Kerbauy J. Acute promyelocytic leukemia: the study of t(15;17) translocation by fluorescent in situ hybridization, reverse transcriptase-polymearse chain reaction and cytogentic techniques. Braz J Med Biol Res 2001; 34: 735–743
- Mitelman, F. An International System for Human Cytogenetics Nomenclature (ISCN). Karger, BaselSwitzerland 1995
- Appelbaum F R, Rowe J M, Radich J, Dick J E. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2001; 62–86
- Kanamaru A, Takemoto Y, Tanimoto M, Muramaki H, Asou N, Kobayashi T, et al. All trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Study Group. Blood 1995; 85: 1202–1206
- Arruda V R, Lima C SP, Grignoli C RE, Melo M B, Lorand-Metze I, Alberto F L, et al. Increased risk for acute myeloid leukaemia in individulas with glutathione S-transferase µ1 (GSTM1) and θ1 (GSTT1) gene defects. Eur J Haematol 2001; 66: 383–388
- Bowen D T, Frew M E, Rollinson S, Roddam P L, Dring A, et al. CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated with FLT3 internal tandem duplication. Blood 2003; 101: 2770–2774
- Basu T, Gale R E, Fidler C, Peto P E, Boutwood J, Wainscoat J S. Glutahione S-transferase theta 1 (GSTT1) gene defect in myelodysplasia and acute myeloid leukemia. Lancet 1997; 349: 1450
- Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer 2006; 107: 2099–2107
- Phekoo K J, Richards M A, Møller H, Schey S A. The incidence and outcome of myeloid malignancies in 2,112 adult patients in South East-England. Haematologica 2006; 91: 1400–1404
- Lipshultz S E, Lipsitz S R, Mone S, Goorin A M, Sallan S E, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. NEJM 1995; 332: 1738–1744